News | March 11, 2023
Marksans Pharma announces USFDA approval for Famotidine Tablets
Marksans' OTC Famotidine Tablets USP are acid reducers
Marksans' OTC Famotidine Tablets USP are acid reducers
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Subscribe To Our Newsletter & Stay Updated
